Editas Medicine Inc. (EDIT) Upgraded by Zacks Investment Research to “Hold”

Editas Medicine Inc. (NASDAQ:EDIT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “

Separately, Jefferies Group upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Wednesday, August 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Editas Medicine currently has an average rating of “Buy” and a consensus price target of $33.50.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Shares of Editas Medicine (NASDAQ:EDIT) traded up 0.72% during midday trading on Wednesday, hitting $13.91. 123,614 shares of the company’s stock were exchanged. The stock’s market cap is $492.47 million. Editas Medicine has a 1-year low of $12.57 and a 1-year high of $43.99. The stock’s 50 day moving average is $14.92 and its 200-day moving average is $25.92.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). Analysts predict that Editas Medicine will post ($2.59) earnings per share for the current fiscal year.

In other Editas Medicine news, major shareholder Kevin P. Starr sold 5,890 shares of Editas Medicine stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $15.90, for a total transaction of $93,651.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Polaris Venture Management Co. sold 500,000 shares of Editas Medicine stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $8,400,000.00. The disclosure for this sale can be found here.

A number of hedge funds and other institutional investors have recently made changes to their positions in EDIT. Deerfield Management Co. purchased a new position in Editas Medicine during the first quarter worth approximately $59,043,000. State Street Corp purchased a new position in Editas Medicine during the first quarter worth approximately $1,191,000. JPMorgan Chase & Co. purchased a new position in Editas Medicine during the first quarter worth approximately $2,504,000. Goldman Sachs Group Inc. purchased a new position in Editas Medicine during the first quarter worth approximately $2,405,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Editas Medicine during the first quarter worth approximately $336,000. 61.03% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

5 Day Chart for NASDAQ:EDIT

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.